Investigational agent improves interstitial cystitis pain

Article

An investigational bladder instillation appears to improve daytime pain in patients with painful bladder syndrome/interstitial cystitis in a single dose, according to interim results of a phase II study.

An investigational bladder instillation appears to improve daytime pain in patients with painful bladder syndrome/interstitial cystitis in a single dose, according to interim results of a phase II study.

The multicenter, double-blind, crossover study compared URG101, a lidocaine and heparin solution, with placebo in 21 patients.

URG101 was significantly better than placebo in the primary efficacy measurement of improvement in daytime pain (p=.03). The drug also fared better than placebo in the secondary endpoints of improvement in daytime urgency (p=.03) and total symptom score (p=.03). In addition, patients reported improved symptom relief with the pharmaceutical treatment as measured by patients’ overall ratings of improvements of symptoms (p=.01), according to Urigen Pharmaceuticals, the drug’s manufacturer.

Additional analyses are ongoing. Results will be used to gauge whether additional patients will be enrolled in the study, which is designed for 50 subjects.

Related Videos
Dr. Christopher Wallis in an interview with Urology Times
Randall A. Lee, MD, answers a question during a Zoom video interview
Edward M. Schaeffer, MD, PhD, answers a Zoom video interview question
Man talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
James Ferguson III, MD, PhD, answers a question during a Zoom video interview
Nicholas L. Kavoussi, MD, answers a question during a Zoom video interview
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Paul M. Yonover, MD, FACS, an expert on prostate cancer
© 2023 MJH Life Sciences

All rights reserved.